Fig. 10

RBM15-mediated m6A modification reduces cisplatin resistance in LC cells by inhibiting ferroptosis. DDP-resistant cells with stably downregulated RBM15 were injected into nude mice. (A-B): Tumor volume and weight were measured (representative images of the tumors); (C): Ki67 positivity rate was detected by IHC; (D): Expression of RBM15, KDM5B, KCNQ1OT1, and FER1L4 was assessed by RT-qPCR; (E-F): Levels of RBM15, KDM5B, ACSL4, and GPX4 were determined by Western blot assay; (G): Iron content, ROS level, MDA level, and GSH content in the tissues. N = 6. The experiments were independently repeated three times, and the data are expressed as mean ± standard deviation. Data in panels B, C, D, and G: comparison between the two groups was analyzed using t-tests; data in panels A and E: comparisons among multiple groups were analyzed using two-way ANOVA, followed by Tukey’s multiple comparisons test. ** p < 0.01